NuBCP-9 for Cancer Therapy: A Nanotechnological Approach
Published Date: December 07, 2017
NuBCP-9 for Cancer Therapy: A Nanotechnological Approach
Sumeet Kapoor1*, Swati Ojha2, Aji Alex3, and Amit K. Gupta4
1,3Centre for Biomedical Engineering, Indian Institute of Technology Delhi, India
2Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology Delhi, India
4Department of Mechanical Engineering, Indian Institute of Technology Delhi, India
*Corresponding author: Sumeet Kapoor, Centre for Biomedical Engineering, Indian Institute of Technology Delhi, India, E-mail: email@example.com
Citation: Kapoor S, Ojha S, Alex A, Gupta AK (2017) Fluorescence Quenching of Graphene Quantum Dots by Titania Nanoparticles in Water Analysis after Coating with Polydopamine. J Mol Nanot Nanom 1(2): 108.
Chemotherapeutics are antineoplastic agents that are widely used for number of malignancies but they cause toxicity and development of multidrug resistance . Therapeutics peptides (TP’s) represent a new wave of anticancer agents which have shown promising results . They inhibit or mimic protein–protein interactions in a specific manner that may lead to induction of apoptosis or cell death. Although TP’s are biocompatible and target specific but they suffer from drawbacks of degradation by serum proteases and generation immune response. Modification of amino acid skeleton like addition of unnatural D-amino acids in peptide sequence  or glycosylation can protect TP’s from degradation by proteases but systemic circulation is difficult to attain .
NuBCP-9 is a small therapeutic peptide (short amino acid consisting of nine amino acids) that selectively kills cancer cells . The mechanistic pathway of NuBCP-9 is shown in figure 1. Binding of NuBCP-9 to BH4 domain of BCL-2 protein in the outer mitochondrial membrane protein induces conformation change in such a way that it become apoptotic from its anti-apoptotic function that evenly leads to apoptosis by induction of caspases . However, NuBCP-9 alone undergoes proteolytic cleavage and evoke immune response thus cannot enter the target cell.
In some reports delivery of NuBCP-9 conjugated to cell penetrating peptides (CPP)  and super paramagnetic iron oxide nanoparticles (SPIONs) have been reported . Merck KGaA, Darmstadt, Germany is supplying CPP conjugated NuBCP-9 for various research studies. However, CPP causes membrane blebbing and necrosis in the target cells and SPIONs are still under clinical trials for various cancer therapy applications.
Myriad number of nanocarriers prepared from biodegradable polymers like polylactic acid, polycaprolactone, polyglycolic acid and polyhydroxybutyrate has been successfully employed for delivery of number of anticancer agents . These polymers are approved by FDA as they produce nontoxic metabolites in the body after metabolism.
Nanotechnological approach for delivery of NuBCP-9 using polylactic acid  and polyhydroxybutyrate  were reported and confirmed the superiority of this approach over other previously opted approaches. The approach precludes all drawbacks faced by CPP and SPIONs.
Monaj et al. have reported 74% tumor regression with NuBCP-9 peptide conjugated superoxide iron oxide nanoparticles whereas a complete regression was observed with NuBCP-9 peptide encapsulated polylactic acid copolymeric nanoformulations in BALB/c mice bearing Ehrlich syngeneic tumors. NuBCP-9 encapsulated polyhydroxybutyrate based nanoformulation showed 90% tumor regression under in vivo conditions .
NuBCP-9 has great potential as anticancer agents and polymeric nanocarriers can increase their scope to a level where they can completely replace existing chemotherapeutic agent and drugs.
- Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52-79. doi: 10.1016/j.ejpb.2015.03.018.
- Patel A, Patel M, Yang X, Mitra AK. Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles. Protein Pept Lett. 2014;21(11):1102-20.
- Di L. Strategic Approaches to Optimizing Peptide ADME Properties. AAPS J. 2015;17(1):134-43. doi: 10.1208/s12248-014-9687-3.
- Solá RJ, Griebenow K. Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimiza Efficacy. BioDrugs. 2010;24(1):9-21. doi: 10.2165/11530550-000000000-00000.
- Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, et al. A Short Nur77-Derived Peptide Converts Bcl-2 from a Protector to a Killer. Cancer Cell. 2008;14(4):285-98. doi: 10.1016/j.ccr.2008.09.002.
- Qi B, Hardwick JM. Bcl-2 turns deadly. Nat Chem Biol. 2008;4:722–723.
- Watkins CL, Sayers EJ, Allender C, Barrow D, Fegan C, Brennan P, et al. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. Mol Ther. 2011;19(12):2124-32. doi: 10.1038/mt.2011.175.
- Kumar M, Singh G, Sharma S, Gupta D, Bansal V, Arora V, et al. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9. Nanoscale. 2014;6(23):14473-83. doi: 10.1039/c4nr04504a.
- Kapoor S, Gupta D, Kumar M, Sharma S, Gupta AK, Misro MM, et al. Intracellular delivery of peptide cargos using polyhydroxybutyrate based biodegradable nanoparticles: studies on antitumor efficacy of BCL-2 converting peptide, NuBCP-9. Int J Pharm. 2016;511(2):876-89. doi: 10.1016/j.ijpharm.2016.07.077.
- Kumar M, Gupta D, Singh G, Sharma S, Bhat M, Prashant CK, et al. Novel polymeric nanoparticles for intracellular delivery of peptide cargos: Antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res. 2014;74(12):3271-81. doi: 10.1158/0008-5472.CAN-13-2015.
Copyright: © 2017 Kapoor S, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.